.png)
.png)
Chief Medical Officer
F2G, Limited
Disclosure(s): Advent Life Sciences: Operating Partner, Ownership Interest; AMR Action Fund: Advisor/Consultant; AstraZeneca: Stocks/Bonds; Basilea Pharmaceutica: Advisor/Consultant; Bugworks Research, Inc.: Advisor/Consultant; F2G, Limited: Employee, Stocks/Bonds; Forge Therapeutics: Advisor/Consultant; GlaxoSmithKline: Advisor/Consultant; Pfizer Pharmaceuticals: Honoraria; Sumitovant: Advisor/Consultant
Dr. Rex is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. He is currently CMO for F2G, Ltd. (an antifungal biotech), is an operating partner with a venture capital group (Advent Life Sciences), is Chair of the Scientific Advisory Board of the $1b AMR Action Fund, and was (2015-2019) a voting member on the US Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB). He also blogs regularly at http://amr.solutions/blog.html.
His experience includes moving compounds from preclinical development through all development phases via academic positions (NIH, Bethesda, MD; McGovern Medical School-Houston) and VP-level roles at a multinational pharmaceutical firm (AstraZeneca). Other past activities include advancing novel regulatory paradigms for antibacterials, publications on novel reimbursement models for antibiotics, co-founding of a public-private partnership (CARB-X), co-founding the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and a 4-year term as Industry Representative on the FDA Anti-Infective Drugs Advisory Committee (AIDAC, 2007–2011).